Company / Cash & Equivalents
Lineage Cell Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$40.8M
FY2025
5-year range
$11.4M / $55.7M
FY2021-FY2025
Trend
-10.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $9M in FY2020 to $56M in FY2021.
Based on SEC 10-K filings.
$41M in FY2025 with a 5-year CAGR of +33.8%.
Improved from $35M to $41M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +53.2%
- 5-Year CAGR
- +33.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +33.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 10.9% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $40.8M | -10.9% |
| FY2024 | $45.8M | +29.2% |
| FY2023 | $35.4M | +212.1% |
| FY2022 | $11.4M | -79.6% |
| FY2021 | $55.7M | +486.9% |
| FY2020 | $9.5M | -59.7% |
| FY2019 | $23.6M | -36.0% |
| FY2018 | $36.8M | +66.8% |
| FY2017 | $22.1M | -25.1% |
| FY2016 | $29.5M | +436.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026